Published in Arthritis Rheum on October 01, 2005
DNA methyltransferase 3B gene promoter and interleukin-1 receptor antagonist polymorphisms in childhood immune thrombocytopenia. Clin Dev Immunol (2012) 0.82
A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum (2008) 0.79
The Clinical Significance of Interleukin-1 Receptor Antagonist +2018 Polymorphism in Rheumatoid Arthritis. PLoS One (2016) 0.75
Association of 86 bp variable number of tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL1RN) with susceptibility and clinical activity in rheumatoid arthritis. Clin Rheumatol (2017) 0.75
A link between osteomyelitis and IL1RN and IL1B polymorphisms-a study in patients from Northeast Brazil. Acta Orthop (2017) 0.75
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet (2007) 2.52
Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis. Arthritis Rheum (2012) 2.22
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. Arthritis Res Ther (2009) 1.52
Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum (2008) 1.37
Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther (2009) 1.35
Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol (2003) 1.34
New sequence variants in HLA class II/III region associated with susceptibility to knee osteoarthritis identified by genome-wide association study. PLoS One (2010) 1.27
Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. Arthritis Res Ther (2006) 1.27
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. Arthritis Rheum (2009) 1.23
Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage. BMC Mol Biol (2008) 1.22
Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum (2004) 1.22
Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. Hum Mol Genet (2009) 1.15
Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis (2007) 1.11
A HEV-restricted sulfotransferase is expressed in rheumatoid arthritis synovium and is induced by lymphotoxin-alpha/beta and TNF-alpha in cultured endothelial cells. BMC Immunol (2005) 1.10
Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis (2013) 1.09
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol (2014) 1.03
Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum (2013) 1.02
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis (2010) 1.01
Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations. J Rheumatol (2012) 1.00
Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) (2013) 0.99
Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97
Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One (2009) 0.96
Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum (2008) 0.96
Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheum (2009) 0.93
Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis Rheum (2004) 0.92
Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum (2010) 0.91
Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest (2010) 0.91
Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun (2007) 0.91
Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, eotaxin-3, and MHC2TA. J Rheumatol (2009) 0.90
Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study. PLoS One (2012) 0.90
Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther (2010) 0.89
Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. Arthritis Res Ther (2012) 0.89
Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis. Arthritis Rheum (2008) 0.88
Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies. Rheumatology (Oxford) (2009) 0.88
Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum (2012) 0.86
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) (2010) 0.86
Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis. Arthritis Rheum (2011) 0.86
Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther (2006) 0.85
Association of systemic lupus erythematosus clinical features with European population genetic substructure. PLoS One (2011) 0.85
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis (2012) 0.85
Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford) (2013) 0.84
Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. Arthritis Res Ther (2011) 0.82
A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum (2004) 0.81
Optimising stable retroviral transduction of primary human synovial fibroblasts. J Virol Methods (2006) 0.81
Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum (2006) 0.81
Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. Rheumatol Int (2013) 0.80
A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum (2008) 0.79
Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. Arthritis Rheum (2005) 0.79
SLC22A4, RUNX1, and SUMO4 polymorphisms are not associated with rheumatoid arthritis: a case-control study in a Spanish population. J Rheumatol (2006) 0.79
Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. Ann Rheum Dis (2007) 0.77
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Ther (2014) 0.77
Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis. Arthritis Res Ther (2012) 0.77
Association of a BMP5 microsatellite with knee osteoarthritis: case-control study. Arthritis Res Ther (2012) 0.77
Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II. Peptides (2005) 0.76
Lymphoid aggregation is not lymphoid neogenesis: comment on the article by Klaasen et al. Arthritis Rheum (2010) 0.76
Tuberculosis in pediatric solid organ and hematopoietic stem cell transplant recipients. Pediatr Infect Dis J (2012) 0.76
Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies. Arthritis Res Ther (2013) 0.76
SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis. J Rheumatol (2006) 0.75
Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus. Arthritis Res Ther (2014) 0.75
Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study. Arthritis Res Ther (2014) 0.75
Reply: Pathogenic relevance of anti-citrullinated vimentin antibodies: comment on the article by Montes et al. Arthritis Rheum (2013) 0.75